Company Overview of Boehringer Ingelheim Ltd UK
Boehringer Ingelheim Ltd UK researches, develops, and manufactures prescription medicines, over-the-counter products, and animal healthcare products in the United Kingdom. The company focuses on various medical conditions, including respiratory, cardiovascular, virology, central nervous system, immunology, and metabolic diseases. It offers products for the treatment of chronic obstructive pulmonary disease, heart attack, secondary stroke prevention and treatment, high blood pressure, thromboembolic disease, HIV/AIDS, Parkinson's disease, stroke, cerebrovascular disease, diabetes, and non-small cell lung cancer. The company also offers consumer healthcare products in the areas of constipation...
Bracknell, RG12 8YS
Founded in 1955
Key Executives for Boehringer Ingelheim Ltd UK
Finance & Administration Director
Senior Vice President of Global Biopharma Operations
Head of Established Markets
Compensation as of Fiscal Year 2016.
Boehringer Ingelheim Ltd UK Key Developments
Boehringer Ingelheim Limited Presents at 9th Annual BioPharm America International Partnering Conference - BioPharm America 2016, Sep-14-2016 10:00 AM
Aug 12 16
Boehringer Ingelheim Limited Presents at 9th Annual BioPharm America International Partnering Conference - BioPharm America 2016, Sep-14-2016 10:00 AM. Venue: Marriott Copley Place, Boston, Massachusetts, United States. Speakers: Imran Nasrullah.
Boehringer Ingelheim Limited Wins GBP 106.5 Million Multiple Awardees Contract for Proprietary Pharmaceuticals
Mar 4 16
Boehringer Ingelheim Ltd. won a GBP 106.5 million multiple awardees contract award from The Secretary of State for Health acting as part of the Crown through the Commercial Medicines Unit (part of the Department of Health) for proprietary pharmaceuticals (Contract Award Notice No.: 2016/S 044-072447). NHS Framework Agreement for Proprietary Pharmaceuticals for the Midlands and East Pharmacy Purchasing Group: Period 1.3.2016 to 28.2.2018 with an option to extend for 24 months. Hepatitis C drugs for the above region: Period 1.3.2016 to 28.2.2017 with an option to extend for 12 months.
Boehringer Ingelheim Ltd Wins GBP 567.5 Million Multiple Awardees Contract for Pharmaceutical Products
Feb 5 16
Boehringer Ingelheim Ltd. won a GBP 567.5 million (excluding VAT) multiple awardees contract award from The Secretary of State for Health acting as part of the Crown through the Commercial Medicines Unit (part of the Department of Health) for pharmaceutical products (Contract Award Notice No.: 2016/S 023-036546).
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|